As of Friday close, Lexicon Pharmaceuticals Inc.’s (NASDAQ:LXRX) stock was up $0.14, moving up 5.20 percent to $2.83. The average number of shares traded per day over the past five days has been 2,421,920 shares. 5 times new highs have been achieved over the past 5 days, with a $0.45 gain in that time frame. In the last twenty days, the average volume was 1,593,710, while in the previous 50 days, it was 1,819,496.
Since last month, LXRX stock rose 0.71%. Shares of the company fell to $2.34 on 08/01/22, the lowest level in the past month. A 52-week high of $6.33 was reached on 01/04/22 after having rallying from a 52-week low of $1.31. Since the beginning of this year, LXRX’s stock price has dropped by -28.17% or -$1.11, and marked a new high 2 times. However, the stock has declined by -55.29% since its 52-week high.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Lexicon Pharmaceuticals Inc. (LXRX) last reported insider trading activity 5 days ago on Aug 01. Artal International S.C.A., the Director of the company, purchased of 16,173,800 shares for $2.50 on Aug 01. It resulted in a $40,434,500 investment by the insider. Invus US Partners LLC added 982,600 shares at an average price of $2.50 on Aug 01. The insider now owns 5,303,814 shares following the transaction. On Aug 01, Director DEBBANE RAYMOND bought 982,600 shares at $2.50 apiece. The transaction was valued at $2,456,500.
The stock’s beta is 1.50. Besides these, the trailing price-to-sales (P/S) ratio of 1939.02, the price-to-book (PB) ratio of 4.56.
According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.25. Based on annual data, LXRX earned $0.3 million in gross profit and brought in $0.3 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -76.70%. Return on equity (ROE) for the past 12 months was -75.20%.
In Lexicon Pharmaceuticals Inc.’s quarter-end financial report for June 29, it reported total debt of $23.63 million against cash and short-term investments of $40.52 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. While analysts expected Lexicon Pharmaceuticals Inc. to report -$0.16 quarterly earnings, the actual figure was -$0.16 per share. During the quarter, the company generated -$23.75 million in EBITDA. The liabilities of Lexicon Pharmaceuticals Inc. were 41.49 million at the end of its most recent quarter ended June 29, and its total debt was $23.63 million. The value of shareholders’ equity is $183.63 million.
This quick technical analysis looks at Lexicon Pharmaceuticals Inc.’s (LXRX) price momentum. With a historical volatility rate of 174.90%, the RSI 9-day stood at 54.57% on 05 August.
With respect to its five-day moving average, the current Lexicon Pharmaceuticals Inc. price is up by +18.91% percent or $0.45. At present, LXRX shares trade -1.39% below its 20-day simple moving average and +44.39% percent above its 100-day simple moving average. However, the stock is currently trading approximately +74.69% above its SMA50 and -43.74% below its SMA200.
Stochastic coefficient K was 41.75% and Stochastic coefficient D was 32.63%, while ATR was 0.24. Given the Stochastic reading of 51.58% for the 14-day period, the RSI (14) reading has been calculated as 55.05%. As of today, the MACD Oscillator reading stands at 0.03, while the 14-day reading stands at -0.10.